Accepting Help and Receiving Kindness

I wrote last week about how the inaction and silence of others can be deafening. The opposite is also true. When help is offered and the offer is followed up on, it can leave you speechless, humbled, and grateful. And those who step up to help often are not…

Soleo Health, a pharmacy specializing in infusion therapies, will serve as the U.S. distributor that will administer Vyvgart (efgartigimod), the newly approved treatment for people with generalized myasthenia gravis (gMG). Argenx, the therapy’s developer, selected Soleo Health as a limited distribution partner for Vyvgart, which was approved…

Japan has approved Vyvgart (efgartigimod) to treat adults with generalized myasthenia gravis (gMG), the therapy’s developer, Argenx, announced. Vyvgart will be available to generalized MG patients, regardless of antibody status, who are refractory, which means they have failed to respond to steroids or nonsteroidal immunosuppressive therapies. The…

One of the hardest things about living with a chronic illness like myasthenia gravis (MG) is the dialogue that doesn’t happen with people we know. The eye rolls we perceive when we try to update loved ones about our health status — whether they’re real or not. Or the phone…

Tacrolimus is effective and safe as a single-agent immunotherapy for people with myasthenia gravis (MG), and its use led to minimal manifestation status in a majority of patients treated for one year in China, a study reported. Favorable responses were particularly evident in younger patients (up to age 40),…

A powerful imagination can be both a gift and a curse. On one hand, it can be a way for us to brainstorm and envision ideas. In a way, it can help us make a plan for the goals we want to reach. On the other hand, it can…

Scientists described a new cellular model of the neuromuscular junction that could be useful for diagnosing myasthenia gravis (MG) or developing new treatments for the condition. “New approaches for the treatment of neurodegenerative diseases are sorely needed, as decades of research have resulted in limited therapeutic advances. We hope…

Many of my friends, colleagues, and family members set goals for the year in January. Goals can be personal or professional, interpersonal or financial, realistic or not. What makes a goal realistic, particularly for someone with myasthenia gravis (MG)? It’s a tough question to answer, but I’ll do my best.

By analyzing available research and conducting nearly 100 interviews with patients, an international team of researchers crafted a new tool to measure the severity of myasthenia gravis (MG) based on patient experiences. Called MG Symptoms PRO, this tool has the potential to aid clinical trials by better capturing a…

Argenx is working toward the commercial launch of Vyvgart (efgartigimod) — recently approved by the U.S. Food and Drug Administration (FDA) — to treat adults in the U.S. with generalized myasthenia gravis (gMG) who have the most common type of MG-driving antibody. Vyvgart currently is up for…